Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 7/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.40 |
| ▸ | PTGIR | P43119 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492996 | 0.93 | KMT2A (0.40) | CXCR3TAS2R14KMT2AMEN1NR1H4 | |
| SCHEMBL492940 | 0.92 | CXCR3 (0.47) | CXCR3TAS2R14PTGIRKMT2AMEN1 | |
| SCHEMBL492241 | 0.92 | TAS2R14 (0.44) | CXCR3TAS2R14PTGIRKMT2AMEN1 | |
| SCHEMBL493377 | 0.90 | NPSR1 (0.42) | TAS2R14KMT2AMEN1NR1H4TACR3 | |
| SCHEMBL492554 | 0.89 | CXCR3 (0.40) | CXCR3PTGIR | |
| SCHEMBL493247 | 0.87 | AVPR1A (0.37) | CXCR3PTGIR | |
| SCHEMBL492655 | 0.87 | CXCR3 (0.51) | CXCR3TAS2R14KMT2AMEN1 | |
| SCHEMBL493251 | 0.86 | HTR6 (0.38) | PTGIRKMT2AMEN1 | |
| SCHEMBL492261 | 0.84 | TAS2R14 (0.43) | CXCR3TAS2R14KMT2AMEN1NR1H4 | |
| SCHEMBL493346 | 0.84 | HTR6 (0.37) | PTGIRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | CXCR3 4458/4885TAS2R14 1127/4885PTGIR 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.